Whitepaper: Enhancing Outcomes in Transplant Recipients Through Advanced Biomarker Profiling

At the forefront of transplant medicine, advanced biomarker profiling is revolutionizing post-transplant care. Traditionally, biopsies were used to monitor the health of transplanted organs, but these procedures can be invasive and uncomfortable. Now, new noninvasive tests like TRAC (donor-derived cell-free DNA) and TruGraf (gene expression profiling) are transforming how doctors detect transplant issues early and manage patient care more effectively.

These tests allow for earlier detection of organ rejection or injury without the need for biopsies, enabling doctors to make informed decisions about immunosuppressive medications—those critical drugs that prevent the body from rejecting a transplanted organ. By personalizing care for each patient, TRAC and TruGraf help avoid unnecessary treatments while ensuring optimal protection for the transplanted organ.

Leading experts in the field, such as Dr. John Friedewald from Northwestern Memorial Hospital, Dr. V. Ram Peddi from California Pacific Medical Center, and Dr. Michael Marvin from Geisinger Health System, have successfully implemented these tests in clinical settings. Their case studies demonstrate how these innovative tests guide medication adjustments, improve patient outcomes, and enhance the overall quality of life for transplant recipients.

With these cutting-edge biomarker tests, the future of transplant care is brighter, offering more precise and patient-friendly solutions. Learn more about how TRAC and TruGraf are changing the landscape of transplant medicine.

Want to learn more? Fill out the form and read the whitepaper for an in-depth study.